A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma szansę przeżyć co najmniej 12 tygodni.
- •Ogólny stan zdrowia pacjenta pozwala na uczestnictwo w badaniu (skala 0-2).
- •Potwierdzony rak płuca z mutacją EGFR lub rak głowy/szyi.
- •Rak płuca lub głowy/szyi jest zaawansowany lub rozprzestrzeniony.
- •Narządy pacjenta funkcjonują prawidłowo.
✗ Disqualifies
- •Pacjent ma chorobę, której nie udało się opanować.
- •Pacjent ma objawowe przerzuty do mózgu.
- •Pacjent chorował na inny nowotwór w ciągu ostatnich 3 lat (chyba że był leczony i nie ma oznak choroby).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
Site 105 - START Los Angeles
Los Angeles, United States
Site 104 - START New Jersey
East Brunswick, United States
Site 107 - START New York - Long Island
Lake Success, United States
Sarah Cannon and HCA Research Institute
Nashville, United States
MD Anderson Cancer Center
Houston, United States
Site 102 - START San Antonio
San Antonio, United States
Samsung Medical Center
Seoul, South Korea
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
Kaohsiung City, Taiwan
Trial contact
EpiBiologics Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.